*Please Note: Links to full articles may expire after 2 weeks. If you are unable to access the page via the links below, try searching the HBV Research List Archives at http://archive.mail-list.com/hbv_research/
IL-23 Predicts PegIFN Response in Chronic HBV
Feb 23 - High baseline serum levels of interleukin (IL)-23 can help to identify hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who are likely to respond to pegylated interferon (PegIFN) treatment, a Chinese study indicates. Read more.
TDF Monotherapy ‘Reasonable’ Option in Entecavir-Resistant HBV
Feb 23 - The efficacy of tenofovir disoproxil fumarate (TDF) monotherapy is comparable to that of TDF plus entecavir in chronic hepatitis B patients with genotypic resistance to entecavir, according to researchers from the Republic of Korea. Read more.
Antiviral Treatment Improves Survival in Sorafenib-Treated Hepatitis B Related Hepatocellular Carcinoma
Feb 23 - For sorafenib-treated patients with hepatitis B virus-related hepatocellular carcinoma, antiviral therapy with nucleoside analogues is associated with improved survival, according to a study published online in theJournal of Gastroenterology and Hepatology. Read more.
Government Panel Recommends FIVE CUPS of Coffee a Day to Ward Off Heart Disease, Liver Cancer and Parkinson's
Feb 23 – A panel of experts from the Dietary Guidelines Advisory Committee, which convenes every five years, did a detailed assessment of coffee for the first time, and suggests 3-5 cups of the caffeinated beverage may help keep the doctor away, along with reducing the risk of liver cancer. Read more.
50th Anniversary of Dr. Baruch S. Blumberg’s First Paper on the Hepatitis B Virus
Feb 16 – Known at the time as the “Australia Antigen”, this original publication, written by Dr. Baruch S. Blumberg, looks at the identification of the hepatitis B surface antigen, and was published in JAMA. Dr. Blumberg and his team were responsible for the discovery of the hepatitis B virus and subsequent diagnostics and vaccine to identify and prevent hepatitis B infection. Dr. Blumberg was awarded the Nobel Prize in 1976 for his discovery of the hepatitis B virus, and was instrumental in establishing the Hepatitis B Foundation in 1991. Read more.
Hot On The Trail Of The Hepatitis-Liver Cancer Connection
Feb 16 – For the first time, scientists have demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer. Read more.
Galapagos Gets EUR1.6 Mln IWT Grant For Hepatitis B Program
Feb 16 – The Flemish Agency for Innovation through Science and Technology has awarded a 1.6 million euros grant to support the development of new antiviral therapies against hepatitis B. Read more.
Reactivation of Hepatitis B Can Be Prevented and Treated During Immunosuppressive Drug Therapy
Feb 9 – Long-term immunosuppressive therapy can cause the hepatitis B virus to reactivate, even in patients who are not aware that they are infected with HBV. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others. Read more.
Gut Microbes May Play a Role in Age-Related Hepatitis B Virus Clearance
Feb 9 – Treating adult mice with antibiotics to wipe out their intestinal microbiota made them unable to naturally clear hepatitis B, so they became more like young mice that developed chronic infection. The researchers also showed that mice lacking toll-like receptor 4 (TLR4) cleared HBV regardless of age. Read more.
Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB
Feb 9 – President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for viral hepatitis efforts by significantly increasing the budget for CDC Division of Viral Hepatitis, which has been underfunded relative to number of people affected by viral hepatitis. Get involved with federal advocacy and let your legislators know that funding for hepatitis B is important to you. Read more.
Liver Cancer Australia’s Most Deadly Cancer
Feb 9 – February 4th was World Cancer Day, and new analysis shows liver cancer looms as Australia's greatest cancer challenge, with one Australian dying of liver cancer for every Australian who is diagnosed with the disease. Read more.
A New Approach to Hepatitis B Therapy?
Feb 2 – Cyclophilins are involved in multiple steps of the hepatitis B virus life cycle in hepatocytes. A new approach is proposed involving a combination of a direct antiviral agent plus a cyclophilin inhibitor. Read more.
Age and HBsAg Level Predict NA-Induced HBeAg Seroconversion Durability
Feb 2 – The combination of age and baseline HBsAg level can help predict hepatitis B virus relapse in patients who achieve HBeAg loss or seroconversion following nucleos(t)ide analogue treatment. Read more.
Long-Term Effects of Antivirals in Patients with HBV-Related Cirrhosis
For patients with HBV-related decompensated cirrhosis, use of oral antivirals initiated early in treatment could have significant benefits in reducing the need for liver transplantation and improving long-term outcomes. Read more.
Discrimination 'Still Rampant’ Among Filipinos with Hepatitis B
Feb 2 - Despite efforts to increase public awareness on Hepatitis B, advocates fighting to eradicate the disease say discrimination against patients is "still rampant” in the Philippines. Read more.
Anti-viral Regimens Did Not Increase Risk for Renal Effects in HBV
Jan 26 – Anti-viral therapy did not increase the risk for renal disease among patients with hepatitis B, with or without renal risk factors before treatment, according to study data. Read more.
NIH Announces Funding for New Technologies for Viral Hepatitis
Jan 26 – The National Institutes of Health (NIH) has issued a funding opportunity announcement to encourage small businesses to address viral hepatitis research opportunities delineated in the Viral Hepatitis Action Plan. Read more.
Livers Kept Healthier for Transplant by New Machine-Perfusion Organ Preservation System
Jan 26 – A new preservation system that pumps cooled, oxygen-rich fluid into donor livers not only keeps the organs in excellent condition for as long as nine hours before transplantation, but also leads to dramatically better liver function and increases survival of recipients, according to a series of animal studies by researchers. Read more.
Falling Through the Cracks: Mothers With Hepatitis B Receive Inadequate Treatment, Follow-up
Jan 19 – More than one-third of women with the hepatitis B virus are initially diagnosed with the infection at their first prenatal care visit, but they do not receive follow-up care for the infection after their pregnancy, researchers have found. Read more.
FDA Orders Partial Hold on Arrowhead HBV Drug Trial
Jan 19 – Arrowhead Research this week announced that the US Food and Drug Administration ordered a partial hold on a planned Phase IIb trial of ARC-520, the company's RNAi-based drug candidate for hepatitis B. Read more.
Cancer 'Bad Luck' Theory Strongly Questioned by WHO Specialized Agency
Jan 19 – The International Agency for Research on Cancer (IARC), WHO’s specialized cancer agency, strongly disagrees with the recent scientific report suggesting random mutations, or “bad luck” as the major contributor to cancer overall. Hepatitis B is highlighted with declines in liver cancer noted in countries with increased hepatitis B vaccination rates. Read more.
Scientists Claim Coffee Protects Our Liver
Jan 19 – The results of the recent study suggest that two cups of coffee per day can lower risk of death from liver cirrhosis by 60%, with the exception of cirrhosis caused by the hepatitis B virus infection. Read more.
Hepatitis B Patients Benefit from New Co-Payment Assistance
Jan 12 – Patient Advocate Foundation is pleased to announce the addition of a new assistance fund to their Co-Pay Relief program dedicated to assisting insured Hepatitis B patients with out of pocket pharmaceutical expenses. Read more.
Canada's Tekmira to Buy U.S.-Based OnCore Biopharma, Focus on HBV Treatment
Jan 12 – Canada's Tekmira Pharmaceuticals Corp agreed to buy Pennsylvania-based OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods. Read more.
Viral Hepatitis Prevention Coordinators, a Vital CDC Program Helping to Achieve the Goals of the Viral Hepatitis Action Plan
Jan 12 – Viral Hepatitis Prevention Coordinators (VHPCs) are vital to the implementation of the nation’s Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis, and ultimately, achievement of 3 of the national goals of reducing viral hepatitis transmission and disease. Read more.
Ugandan Govt Urged on Hepatitis B, the Forgotten Killer
Jan 12 – People living with hepatitis B have urged the Ugandan government to adopt policies and guidelines to fight the disease, whose spread is reportedly on the rise. Read more.
Neonatal HBV Vaccination Reduces the Risk of Liver Cancer and Other Liver Diseases in Young Adults in China
Jan 5 – Neonatal HBV vaccination reduces the risk of liver cancer and other liver diseases in young adults in China, according to a study based on long-term outcomes from a large, randomized controlled study. Read more.
Two-Thirds of Adult Cancers Largely Due to Bad Luck
Jan 5 – A new statistical model created by Johns Hopkins researchers may help measure the proportion of cancers caused by random mutations during stem cell division versus those related to environmental factors and heredity. Liver cancer incidence appeared to be a combination of both, as it is often associated with viral hepatitis. Read more.
Liver Cirrhosis More Common Than Previously Thought
Jan 5 – Cirrhosis of the liver is more common than previously thought, affecting more than 633,000 adults yearly, according to a study published in the Journal of Clinical Gastroenterology. Read more.
ILBS Designated as WHO Collaborating Centre on Viral Hepatitis
Jan 5 – The Institute of Liver and Biliary Sciences (ILBS) has been designated as a WHO Collaborating Centre (WHOCC) on viral hepatitis and liver diseases. Asia houses over 75% of hepatitis B and C and liver cancer cases, and India has close to 60 million such patients. Read more.
Archived News Stories
*Please Note: Links to archived articles may have expired. If you are unable to access the page via the links below, try searching the HBV Research List Archives at http://archive.mail-list.com/hbv_research/